MCID: DRM014
MIFTS: 54

Dermatofibrosarcoma Protuberans malady

Genetic diseases, Rare diseases, Skin diseases, Cancer diseases categories

Aliases & Classifications for Dermatofibrosarcoma Protuberans

About this section
Sources:
49OMIM, 10Disease Ontology, 45NIH Rare Diseases, 22GeneTests, 23Genetics Home Reference, 47Novoseek, 12DISEASES, 51Orphanet, 65UMLS, 36MeSH, 59SNOMED-CT, 37MESH via Orphanet, 66UMLS via Orphanet
See all sources

Aliases & Descriptions for Dermatofibrosarcoma Protuberans:

Name: Dermatofibrosarcoma Protuberans 49 10 45 22 23 47 12 51 65
Dermatofibrosarcoma 23 47 65 36
Dfsp 45 23 51
Metastatic Dermatofibrosarcoma Protuberans 45
 
Familial Dermatofibrosarcoma Protuberans 45
Giant Cell Fibroblastoma 45
Darier-Hoffmann Tumor 23
Darier-Ferrand Tumor 23


Classifications:



Characteristics (Orphanet epidemiological data):

51
dermatofibrosarcoma protuberans:
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: All ages; Age of death: adult


External Ids:

OMIM49 607907
Disease Ontology10 DOID:3507
Orphanet51 31112
MESH via Orphanet37 C538219
UMLS via Orphanet66 C0392784

Summaries for Dermatofibrosarcoma Protuberans

About this section
NIH Rare Diseases:45 Dermatofibrosarcoma protuberans is an uncommon tumor that arises in the skin. the tumor is firm and often flesh-colored although it can be reddish, bluish, or purplish. the tumor is often found on the chest or shoulders, but it can be found on other parts of the body.  dermatofibrosarcoma protuberans may cause no symptoms, and the initial size of the tumor tends to be around 1 to 5 centimeters. this tumor has a low potential to spread to other tissues (metastasize). treatment often involves surgery to remove the tumor, such as by mohs’ micrographic surgery.  last updated: 11/18/2010

MalaCards based summary: Dermatofibrosarcoma Protuberans, also known as dermatofibrosarcoma, is related to fibroma and ring chromosome 5, and has symptoms including thickened skin, neoplasm of the skin and sarcoma. An important gene associated with Dermatofibrosarcoma Protuberans is PDGFB (Platelet-Derived Growth Factor Beta Polypeptide), and among its related pathways are Cytoskeleton remodeling Neurofilaments and Vemurafenib Pathway, Pharmacodynamics. Affiliated tissues include the dermis laryer of the skin, skin and breast, and related mouse phenotypes are embryogenesis and muscle.

Disease Ontology:10 A fibrosarcoma that is located in the dermis laryer of the skin and that begins as a hard nodule and grows slowly.

Genetics Home Reference:23 Dermatofibrosarcoma protuberans is a rare type of cancer that causes a tumor in the deep layers of skin. This condition is a type of soft tissue sarcoma, which are cancers that affect skin, fat, muscle, and similar tissues.

OMIM:49 Dermatofibrosarcoma protuberans (DFSP) is an uncommon, locally aggressive, but rarely metastasizing tumor of the deep... (607907) more...

Wikipedia:68 Dermatofibrosarcoma protuberans (DFSP) is a very rare tumor. It is a rare neoplasm of the dermis layer... more...

Related Diseases for Dermatofibrosarcoma Protuberans

About this section

Diseases related to Dermatofibrosarcoma Protuberans via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 245)
idRelated DiseaseScoreTop Affiliating Genes
1fibroma31.0CD34, TP53
2ring chromosome 530.9COL1A1, PDGFB
3neuroma30.6F13A1, PDGFRA, S100B
4connective tissue disease29.8CD34, COL1A1, PDGFB, PDGFRA, SERPINA3, TP53
5gastrointestinal stromal tumor29.3ACTC1, CD34, DES, PDGFRA, PDGFRB, S100B
6sarcoma10.8
7fibrosarcoma10.8
8fibrous histiocytoma10.7
9histiocytoma10.7
10adult fibrosarcoma10.6
11soft tissue sarcoma10.6
12connective tissue benign neoplasm10.6
13connective tissue cancer10.6
14malignant mesenchymal tumor10.6
15solitary fibrous tumor10.6
16encephalocele10.4
17lipoma10.4
18burn scar10.4
19burns10.4
20merkel cell carcinoma10.4
21spindle cell lipoma10.4
22giant cell tumor10.4
23malignant giant cell tumor10.4
24pancreatitis10.4
25bednar's tumor10.4
26myxofibrosarcoma10.4
27familial isolated hypoparathyroidism due to impaired pth secretion10.3PDGFB, PDGFRB
28steroid inherited metabolic disorder10.3CD34, VIM
29dyskinesia of esophagus10.3F13A1, VIM
30papular xanthoma10.3F13A1, S100B
31body skin hyperlaxity due to vitamin k-dependent coagulation factor deficiency10.3S100B, VIM
32hypersomnia10.3S100B, VIM
33pulmonary fibrosis, familial10.3F13A1, HABP2
34heart valve disease10.3F13A1, VIM
35frontal lobe neoplasm10.3CD34, COL1A1, PDGFB
36gallbladder endocrine tumor10.3S100B, VIM
37severe canavan disease10.3PDGFRA, PDGFRB
38carotenemia10.3NES, VIM
39primary trimethylaminuria10.3PDGFB, PDGFRB
40ophthalmia neonatorum10.3S100B, VIM
41skin squamous cell carcinoma10.3CD163, PDGFB
42differentiating neuroblastoma10.3S100B, VIM
43gynecomastia10.3
44breast cancer10.3
45shwachman-diamond syndrome10.3
46choroid plexus papilloma10.3
47arteriovenous fistula10.3
48keloids10.3
49mycosis fungoides10.3
50sinusitis10.3

Graphical network of the top 20 diseases related to Dermatofibrosarcoma Protuberans:



Diseases related to dermatofibrosarcoma protuberans

Symptoms for Dermatofibrosarcoma Protuberans

About this section


Clinical features from OMIM:

607907

Symptoms:

 51
  • erythema/erythematous lesions/erythroderma/polymorphous erythema
  • thick skin/pachydermia/orange skin
  • subcutaneous nodules/lipomas/tumefaction/swelling
  • skin/cutaneous neoplasm/tumor/carcinoma/cancer (excluding melanoma)
  • soft tissue sarcoma/cancer/tumor/liposarcoma/myosarcoma
  • chronic skin infection/ulcerations/ulcers/cancrum

HPO human phenotypes related to Dermatofibrosarcoma Protuberans:

id Description Frequency HPO Source Accession
1 thickened skin hallmark (90%) HP:0001072
2 neoplasm of the skin hallmark (90%) HP:0008069
3 sarcoma hallmark (90%) HP:0100242
4 skin ulcer typical (50%) HP:0200042

Drugs & Therapeutics for Dermatofibrosarcoma Protuberans

About this section

Drugs for Dermatofibrosarcoma Protuberans (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 12)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
MechlorethamineapprovedPhase 341051-75-24033
Synonyms:
.Beta.,.beta.'-Dichlorodiethyl-N-methylamine
1, 5-Dichloro-3-methyl-3-azapentane hydrochloride
126-85-2 (N-oxide)
2,2'-Dichloro-N-me
2,2'-Dichloro-N-methyldiethylamine
2,2'-Dichlorodiethyl-methylamine
2,2'-dichloro-N-methyldiethylamine
2-Chloro-N-(2-chloroethyl)-N-methylethanamine
302-70-5 (N-oxide, hydrochloride)
51-75-2
55-86-7 (HYDROCHLORIDE)
AC1L1H9H
Antimit
BRN 0605323
BSPBio_001947
Bis(2-chloroethyl)methylamine
Bis(beta-chloroethyl) methylamine
Bis(beta-chloroethyl)methylamine
C07115
C5H11Cl2N
CCRIS 447
CHEBI:28925
CHEMBL427
CID4033
Carolysine
Caryolysin
Caryolysine
Chloramine (the nitrogen mustard)
Chlorethazine
Chlormethine
Chlormethine (INN)
Chlormethine [INN:BAN]
Chlormethinum [INN-Latin]
Cloramin
Clormetina
Clormetina [INN-Spanish]
D07671
DB00888
Di(2-chloroethyl)methylamine
Dichlor amine
Dichloren
DivK1c_000759
EINECS 200-120-5
ENT-25294
Embechine
Embichin
HMS1920J15
HMS2091B04
HMS502F21
HN-2
HN2
HSDB 5083
I14-8708
IBS-L0033631
IDI1_000759
KBio1_000759
KBio2_001369
KBio2_003937
KBio2_006505
KBio3_001447
KBioGR_001448
 
KBioSS_001369
LS-7559
MBA
Me chloroethamine
Mebichloramine
Mechlorethamine
Mechlorethamine hydrochloride
Mechlorethanamine
Mechloroethamine
Mecloretamina
Mecloretamina [Italian]
Methylbis(2-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methyldi(2-chloroethyl)amine
Mitoxine (*Hydrochloride*)
MolPort-001-785-592
Mustargen
Mustine
Mustine note
Mutagen
N,N-Bis(2-chloroethyl)-N-methylamine
N,N-Bis(2-chloroethyl)methylamine
N,N-Di(chloroethyl)methylamine
N-Lost
N-Methyl lost
N-Methyl-2,2'-dichlorodiethylamine
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis-chloraethylamin
N-Methyl-bis-chloraethylamin [German]
N-Methyl-lost
N-Methyl-lost [German]
N-methyl-bis(2-chloroethyl)amine
NCGC00091835-02
NCGC00091835-03
NCGC00091835-04
NCGC00091835-05
NCI60_041682
NINDS_000759
NSC762
Nitol (*Hydrochloride*)
Nitrogen mustard
Nitrogen mustard (HN-2)
Nitrogranulogen
SPBio_000496
SPECTRUM1500375
Spectrum2_000448
Spectrum3_000484
Spectrum4_000924
Spectrum5_001702
Spectrum_000889
Stickstofflost (*Hydrochloride*)
Stickstofflost (ebewe)
T 1024
T-1024
TL 146
UNII-50D9XSG0VR
Valchlor
beta,Beta'-dichlorodiethyl-N-methylamine
beta,beta'-Dichlorodiethyl-N-methylamine
mechlorethamine
thyldiethylamine
β,β'-dichlorodiethyl-N-methylamine
2
IfosfamideapprovedPhase 33583778-73-23690
Synonyms:
(+-)-Ifosfamid
(+-)-Ifosphamide
(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
(D,L)-Ifosfamide
(R,S)-Ifosphamide
(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd
2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
3,} 2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
36341-88-5
3778-73-2
84711-20-6
A 4942
AB00513932
AC-2113
AC1L1GHW
ASTA Z 4942
Ambap3778-73-2
Asta Z 4942
BPBio1_000865
BRN 0611835
BSPBio_000785
C07047
CAS-3778-73-2
CCRIS 352
CHEBI:5864
CHEMBL1024
CID3690
Cyfos
D00343
D007069
DB01181
EINECS 223-237-3
HMS1570H07
HMS2090M12
HMS2093N07
HSDB 7023
Holoxan
Holoxan 1000
I-Phosphamide
I06-0494
IFEX (TN)
Ifex
Ifosfamid
Ifosfamida
Ifosfamida [INN-Spanish]
Ifosfamide
 
Ifosfamide (JAN/USP/INN)
Ifosfamide Sterile
Ifosfamide [USAN:INN:BAN:JAN]
Ifosfamidum
Ifosfamidum [INN-Latin]
Ifosphamide
Ifsofamide
Iphosphamid
Iphosphamid(e)
Iphosphamide
Iso Endoxan
Iso-Endoxan
Isoendoxan
Isofosfamide
Isophosphamide
Isosfamide
LS-102
LS-99799
MJF 9325
MJF-9325
MLS002154021
Mitoxana
Mitoxana, Ifex, Ifosfamide
MolPort-003-666-704
N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide
N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine
NCGC00016639-01
NCGC00179435-01
NCI-C01638
NCI60_000233
NPFAPI-04
NSC 109,724
NSC 109724
NSC-109,724
NSC-109724
NSC109,724
NSC109724
Naxamide
Prestwick0_000833
Prestwick1_000833
Prestwick2_000833
Prestwick3_000833
S1302_Selleck
SMR001233348
SPBio_002706
STL058690
UNII-UM20QQM95Y
WLN: T6NPOTJ AM2G BO B2G
Z 4942
Z-4942
Z4942
ifosfamide
isosfamide
{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,
3
Doxorubicinapproved, investigationalPhase 3, Phase 1152523214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
4
DoxilApproved June 1999Phase 3, Phase 1152531703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
5Isophosphamide mustardPhase 3358
6
Sunitinibapproved, investigationalPhase 2472341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib Malate
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
7
imatinibapprovedPhase 1, Phase 2567152459-95-5644241, 5291
Synonyms:
112GI019
152459-95-5
1iep
1xbb
4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE
4-(4-METHYL-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide
4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide
4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide methanesulfonate
4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide
4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}benzamide
AC-524
AC1L1K0Z
AKOS000280662
BIDD:GT0047
BRD-K92723993-066-02-9
Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI)
CCRIS 9076
CGP 57148B
CGP57148
CGP57148B
CHEBI:45783
CHEMBL941
CID5291
Cgp 57148
D08066
DB00619
DB03261
EN002706
FT-0083542
Glamox
Glamox (TN)
 
Gleevec
Glivec
HMS2089D03
I01-1232
Imatinib
Imatinib (INN)
Imatinib Mesylate
Imatinib Methansulfonate
Imatinib [INN:BAN]
Imatinib free base
Imatinibum
Kinome_3724
LS-182208
LS-187106
MolPort-000-883-342
N-(3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide
NCGC00159456-02
NCGC00159456-03
NCGC00159456-04
NSC743414
STI
STI 571
STI-571
STI571
STK617705
UNII-BKJ8M8G5HI
alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-P-toluidide
alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide
imatinib
nchembio.117-comp23
nchembio.162-comp5
nchembio.282-comp6
nchembio.83-comp14
sti-571
8
PaclitaxelapprovedPhase 1, Phase 2250533069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
9
saracatinibPhase 229
Synonyms:
AZD 0530
 
AZD0530
saracatinib
10taxanePhase 1, Phase 2313
11tyrosineNutraceuticalPhase 1, Phase 2547
12
Cyclophosphamideapproved, investigationalPhase 1252550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
 
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide

Interventional clinical trials:

(show all 20)
idNameStatusNCT IDPhase
1Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue SarcomaRecruitingNCT00334854Phase 3
2Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue SarcomaActive, not recruitingNCT00346164Phase 3
3Imatinib in Dermatofibrosarcoma Protuberans (DFSP)CompletedNCT00122473Phase 1, Phase 2
4Neoadjuvant Imatinib in Dermatofibrosarcoma ProtuberansCompletedNCT00243191Phase 2
5Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma ProtuberansCompletedNCT00084630Phase 2
6Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell FibroblastomaCompletedNCT00085475Phase 2
7Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase EnzymesCompletedNCT00171912Phase 2
8Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic SarcomaCompletedNCT01154452Phase 1, Phase 2
9AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue SarcomaCompletedNCT00659360Phase 2
10Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent SarcomasCompletedNCT00474994Phase 2
11Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesCompletedNCT00154388Phase 2
12To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid TumorsRecruitingNCT01962103Phase 1, Phase 2
13Imatinib Mesylate (Gleevec) in the Treatment of Systemic SclerosisActive, not recruitingNCT00555581Phase 2
14Phase II Pazopanib Study in Advanced DermatofibrosarcomasTerminatedNCT01059656Phase 2
15Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue SarcomaTerminatedNCT00740597Phase 2
16Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib MesylateCompletedNCT01046487Phase 1
17Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue SarcomaActive, not recruitingNCT00720174Phase 1
18Clinical Outcome of Pediatric Dermatofibrosarcoma ProtuberansRecruitingNCT00173355
19Spanish Registry of Mohs SurgeryRecruitingNCT02310503
20Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for SarcomaWithdrawnNCT00334984

Search NIH Clinical Center for Dermatofibrosarcoma Protuberans


Cochrane evidence based reviews: Dermatofibrosarcoma

Genetic Tests for Dermatofibrosarcoma Protuberans

About this section

Genetic tests related to Dermatofibrosarcoma Protuberans:

id Genetic test Affiliating Genes
1 Dermatofibrosarcoma Protuberans22 PDGFB

Anatomical Context for Dermatofibrosarcoma Protuberans

About this section

MalaCards organs/tissues related to Dermatofibrosarcoma Protuberans:

33
Skin, Breast, Lung, Bone, Lymph node, Endothelial, Pancreas

FMA organs/tissues related to Dermatofibrosarcoma Protuberans:

16
The dermis laryer of the skin

Animal Models for Dermatofibrosarcoma Protuberans or affiliated genes

About this section

MGI Mouse Phenotypes related to Dermatofibrosarcoma Protuberans:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053807.8COL1A1, NES, PDGFB, PDGFRA, PDGFRB, TP53
2MP:00053697.5ACTC1, COL1A1, DES, PDGFB, PDGFRA, PDGFRB
3MP:00107717.5CD34, COL1A1, PDGFB, PDGFRA, PDGFRB, S100B
4MP:00053856.8ACTC1, APOD, COL1A1, DES, F13A1, PDGFB
5MP:00053766.5ACTC1, APOD, CD34, COL1A1, DES, F13A1
6MP:00107686.4ACTC1, APOD, COL1A1, DES, F13A1, NES

Publications for Dermatofibrosarcoma Protuberans

About this section

Articles related to Dermatofibrosarcoma Protuberans:

(show top 50)    (show all 568)
idTitleAuthorsYear
1
Dermatofibrosarcoma Protuberans of Lumbar Region with Metastasis to Lung: A Rare Presentation. (26436031)
2015
2
Electrochemotherapy of a Multirecurrent Dermatofibrosarcoma Protuberans of the Orbital Margin: A Case Report. (26504038)
2015
3
Dermatoscopic findings of atrophic dermatofibrosarcoma protuberans. (25692086)
2015
4
Why Is Mohs Micrographic Surgery Underused in the Treatment of Dermatofibrosarcoma Protuberans in Children? (26427735)
2015
5
Dermatofibrosarcoma protuberans, version 1.2014. (24925197)
2014
6
Dermatofibrosarcoma protuberans of the vulva: margins assessment and reconstructive options - a report of two cases. (25547686)
2014
7
Dermatofibrosarcoma protuberans in children and adolescents: Clinical presentation, histology, treatment, and review of the literature. (24973861)
2014
8
Truncal myxoid Dermatofibrosarcoma Protuberans in a 11-month old child. (25163850)
2014
9
Deep dermatofibrosarcoma protuberans in a ninety-year old-woman. (25419747)
2014
10
Outcome of wide local excision in dermatofibrosarcoma protuberans and use of radiotherapy for margin-positive disease. (23741663)
2013
11
Dermatofibrosarcoma protuberans in a 10-year-old child. (24421865)
2013
12
Painful late recurrence of dermatofibrosarcoma protuberans of breast in a centurian female. (24298499)
2013
13
Abdominoplasty and thoraco-epigastric flaps for large anterior trunk defects after dermatofibrosarcoma protuberans wide resection: Two illustrative cases. (23219975)
2013
14
CD99 Expression in Dermatofibrosarcoma Protuberans and Dermatofibroma. (24247571)
2013
15
Magnetic resonance imaging of vulvar dermatofibrosarcoma protuberans - report of a case. (24133389)
2013
16
Practice gaps. Underuse of Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: comment on "efficacy of mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans". (22986860)
2012
17
Dermatofibrosarcoma protuberans: Our experience of 59 cases. (23162649)
2012
18
Dermatofibrosarcoma protuberans in childhood. (23154247)
2012
19
Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection. (20569296)
2011
20
Molecular diagnosis of dermatofibrosarcoma protuberans: a comparison between reverse transcriptase-polymerase chain reaction and fluorescence in situ hybridization methodologies. (21484928)
2011
21
Recurrent bilateral dermatofibrosarcoma protuberans of eyelids. (21346665)
2011
22
Dermatofibrosarcoma protuberans with areas of giant cell fibroblastoma in the vulva: a case report. (21319518)
2010
23
A novel COL1A1 exon 14/PDGFB fusion gene in dermatofibrosarcoma protuberans. (20133221)
2010
24
Imaging of dermatofibrosarcoma protuberans of breast. (20626395)
2010
25
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. (20194851)
2010
26
Surgical treatment for dermatofibrosarcoma protuberans: the Dartmouth experience and literature review. (18443511)
2008
27
Short German guidelines: dermatofibrosarcoma protuberans. (18801137)
2008
28
Atrophic dermatofibrosarcoma protuberans with the fusion gene COL1A1-PDGFB. (18005119)
2008
29
Mohs micrographic surgery and dermatofibrosarcoma protuberans: a multidisciplinary approach in 44 patients. (18520205)
2008
30
Dermatofibrosarcoma protuberans and small bowel adenocarcinoma: coincidental occurrence or genetic association? (18175227)
2006
31
Dermatofibrosarcoma protuberans: report of a case with a variant ring chromosome and metastases following pregnancy. (16640548)
2006
32
Dermatofibrosarcoma protuberans arising in a decorative tattoo. (18521416)
2005
33
Dermatofibrosarcoma protuberans occuring in a child. (15943042)
2005
34
Molecularly targeted treatment for dermatofibrosarcoma protuberans. (15176002)
2004
35
Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature. (15221986)
2004
36
Neurofibromatous changes in dermatofibrosarcoma protuberans: a potential pitfall in the diagnosis of a serious cutaneous soft tissue neoplasm. (15239679)
2004
37
Dermatofibrosarcoma protuberans arising from a burn scar of the axilla. (15084891)
2004
38
Dermatofibrosarcoma protuberans. (15503305)
2004
39
Giant fibrosarcoma arising in dermatofibrosarcoma protuberans on the scalp during pregnancy. (12614428)
2003
40
Dermatofibrosarcoma protuberans of the vulva and groin: detection of COL1A1-PDGFB fusion transcripts by RT-PCR. (12641779)
2003
41
COL1A1-PDGFB gene fusion demonstrates a common histogenetic origin for dermatofibrosarcoma protuberans and its granular cell variant. (12131162)
2002
42
Composite dermatofibrosarcoma protuberans-giant cell fibroblastoma recurring as BednA!r tumor-giant cell fibroblastoma with mucoid lakes and with amputation neuroma. (12629865)
2002
43
Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution. (10870053)
2000
44
A morphologic study of dermatofibrosarcoma protuberans: expansion of a histologic profile. (10774935)
2000
45
Dermatofibrosarcoma protuberans of the head and neck. (11034249)
2000
46
Dermatofibrosarcoma protuberans: what is the best surgical approach? (11128831)
1999
47
Darier-White disease and dermatofibrosarcoma protuberans. (10592418)
1999
48
Acral dermatofibrosarcoma protuberans with metastases. (10029491)
1999
49
A cutaneous case of giant cell angiofibroma occurring with dermatofibrosarcoma protuberans and showing bimodal CD34+ fibroblastic and FXIIIa+ histiocytic immunophenotype. (9696292)
1998
50
Sclerosing dermatofibrosarcoma protuberans. (9826170)
1998

Variations for Dermatofibrosarcoma Protuberans

About this section

Clinvar genetic disease variations for Dermatofibrosarcoma Protuberans:

5
id Gene Variation Type Significance SNP ID Assembly Location
1PDGFBPDGFB, PDGFB/COL1A1 FUSIONundetermined variantPathogenic

Cosmic variations for Dermatofibrosarcoma Protuberans:

7
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1584NRASskin,shoulder,benign melanocytic nevus,congenital1

Expression for genes affiliated with Dermatofibrosarcoma Protuberans

About this section
Search GEO for disease gene expression data for Dermatofibrosarcoma Protuberans.

Pathways for genes affiliated with Dermatofibrosarcoma Protuberans

About this section

GO Terms for genes affiliated with Dermatofibrosarcoma Protuberans

About this section

Cellular components related to Dermatofibrosarcoma Protuberans according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1intermediate filamentGO:000588210.1DES, NES, VIM
2extracellular spaceGO:00056158.1ACTC1, APOD, COL1A1, HABP2, PDGFB, S100B
3extracellular regionGO:00055767.0APOD, CD163, CD34, COL1A1, F13A1, HABP2

Biological processes related to Dermatofibrosarcoma Protuberans according to GeneCards Suite gene sharing:

(show all 26)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathwayGO:003579310.6PDGFB, PDGFRB
2positive regulation of DNA biosynthetic processGO:200057310.6PDGFB, PDGFRB
3positive regulation of chemotaxisGO:005092110.4PDGFB, PDGFRB
4paracrine signalingGO:003800110.4CD34, PDGFB
5positive regulation of calcium ion importGO:009028010.4PDGFB, PDGFRB
6stem cell proliferationGO:007208910.3CD34, NES
7positive regulation of phospholipase C activityGO:001086310.0PDGFRA, PDGFRB
8positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathwayGO:003809110.0PDGFRA, PDGFRB
9metanephric glomerular capillary formationGO:007227710.0PDGFRA, PDGFRB
10negative regulation of platelet activationGO:001054410.0PDGFB, PDGFRA
11response to estradiolGO:00323559.9COL1A1, PDGFB, PDGFRB
12tissue homeostasisGO:00018949.8CD34, PDGFRB
13retina vasculature development in camera-type eyeGO:00612989.8PDGFRA, PDGFRB
14platelet-derived growth factor receptor signaling pathwayGO:00480089.7PDGFB, PDGFRA, PDGFRB
15positive regulation of phosphatidylinositol 3-kinase activityGO:00435529.7PDGFB, PDGFRA, PDGFRB
16cardiac myofibril assemblyGO:00550039.6ACTC1, PDGFRA, PDGFRB
17positive regulation of phosphatidylinositol 3-kinase signalingGO:00140689.6PDGFB, PDGFRA, PDGFRB
18phosphatidylinositol-mediated signalingGO:00480159.6PDGFB, PDGFRA, PDGFRB
19positive regulation of reactive oxygen species metabolic processGO:20003799.6PDGFB, PDGFRB, TP53
20muscle filament slidingGO:00300499.5ACTC1, DES, VIM
21positive regulation of cell migrationGO:00303359.3COL1A1, PDGFB, PDGFRA, PDGFRB
22cell chemotaxisGO:00603269.2PDGFB, PDGFRA, PDGFRB
23positive regulation of gene expressionGO:00106288.9ACTC1, CD34, PDGFB, TP53, VIM
24Ras protein signal transductionGO:00072658.8PDGFB, PDGFRA, PDGFRB, TP53
25response to drugGO:00424938.8ACTC1, APOD, COL1A1, PDGFB, TP53
26wound healingGO:00420608.4COL1A1, F13A1, PDGFB, PDGFRA, PDGFRB

Molecular functions related to Dermatofibrosarcoma Protuberans according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1vascular endothelial growth factor bindingGO:00380859.9PDGFRA, PDGFRB
2platelet-derived growth factor receptor bindingGO:00051619.7PDGFB, PDGFRA, PDGFRB
3platelet-derived growth factor bindingGO:00484079.0COL1A1, PDGFB, PDGFRA, PDGFRB
4identical protein bindingGO:00428028.5COL1A1, DES, PDGFB, S100B, TP53, VIM

Sources for Dermatofibrosarcoma Protuberans

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet